Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

PFIZER INC.

🇺🇸United States

Country: 🇺🇸United States

Ownership: Public

Established: 1849-01-01

Employees: 88K

Market Cap: $163.3B

Website: http://www.pfizer.com

Clinical Trials

Randomized Clinical Trial of Bococizumab (PF-04950615; RN316) in Subjects Who Are Intolerant to Statins

Phase 3

Completed

Conditions: Hyperlipidemia

Interventions: Drug: Bococizumab (PF-04950615;RN316)
Drug: Atorvastatin
Other: Placebo for Bococizumab (PF-04950615;RN316)
Other: Placebo for atorvastatin

First Posted Date: 2014-05-09

Last Posted Date: 2017-12-14

Lead Sponsor: Pfizer

Target Recruit Count: 184

Registration Number: NCT02135029

Locations: 🇺🇸
PMG Research of Knoxville, LLC, Knoxville, Tennessee, United States
🇺🇸
Watson Clinic Center for Research, Inc. (for Drug Shipment only), Lakeland, Florida, United States
🇺🇸
Cardiovascular Research Center Of South Florida, Miami, Florida, United States

and more 37 locations

A Dose Finding Study To Evaluate Safety, Drug Interaction, Tumor Markers Of Axitinib In Combination With MK-3475 In Adult Patients With Previously Untreated Advanced Renal Cell Cancer

Phase 1

Completed

Conditions: Renal Cell Carcinoma

Interventions: Drug: Axitinib
Drug: MK-3475

First Posted Date: 2014-05-08

Last Posted Date: 2021-07-28

Lead Sponsor: Pfizer

Target Recruit Count: 52

Registration Number: NCT02133742

Locations: 🇺🇸
Brigham & Women's Hospital, Boston, Massachusetts, United States
🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

and more 16 locations

Effect Of Itraconazole On The Pharmacokinetics Of Palbociclib

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Palbociclib Alone
Drug: Palbociclib plus itraconazole

First Posted Date: 2014-05-06

Last Posted Date: 2014-06-30

Lead Sponsor: Pfizer

Target Recruit Count: 12

Registration Number: NCT02131298

Locations: 🇺🇸
Pfizer Investigational Site, New Haven, Connecticut, United States

A Multicenter Phase 3, Open-Label Study of Bosutinib Versus Imatinib in Adult Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia

Phase 3

Completed

Conditions: Leukemia, Myelogenous, Chronic, Breakpoint Cluster Region-Abelson Proto-oncogene (BCR-ABL) Positive

Interventions: Drug: Imatinib
Drug: Bosutinib

First Posted Date: 2014-05-05

Last Posted Date: 2021-05-18

Lead Sponsor: Pfizer

Target Recruit Count: 536

Registration Number: NCT02130557

Locations: 🇺🇸
Pacific Cancer Medical Center, Inc., Anaheim, California, United States
🇺🇸
The Emory Clinic, Atlanta, Georgia, United States
🇺🇸
Winship Cancer Institute, Emory University, Atlanta, Georgia, United States

and more 179 locations

A Dose Escalation Study of PF-06650808 in Patients With Advanced Solid Tumors

Phase 1

Terminated

Conditions: Neoplasms
Breast Cancer

Interventions: Drug: PF-06650808

First Posted Date: 2014-05-02

Last Posted Date: 2019-03-29

Lead Sponsor: Pfizer

Target Recruit Count: 40

Registration Number: NCT02129205

Locations: 🇺🇸
Ronald Reagan UCLA Medical Center, Los Angeles, California, United States
🇺🇸
Westwood Bowyer Clinic, Los Angeles, California, United States
🇺🇸
Santa Monica - UCLA Medical Center & Orthopaedic Hospital, Santa Monica, California, United States

and more 8 locations

Concomitant Administration of 13-valent Pneumococcal Conjugate Vaccine (13vPnC) With Influenza Vaccine in 23-valent Pneumococcal Polysaccharide (23vPS) Pre-vaccinated Adults.

Phase 4

Completed

Conditions: PREVENTION OF INVASIVE PNEUMOCOCCAL DISEASE

Interventions: Other: Placebo
Biological: Seasonal Inactivated Influenza Vaccine
Biological: 13-valent pneumococcal conjugate vaccine

First Posted Date: 2014-04-28

Last Posted Date: 2016-07-01

Lead Sponsor: Pfizer

Target Recruit Count: 882

Registration Number: NCT02124161

Locations: 🇺🇸
Achieve Clinical Research, LLC, Birmingham, Alabama, United States
🇺🇸
Optimal Research (Formerly Accelovance), Huntsville, Alabama, United States
🇺🇸
Radiant Research, Inc., Murray, Utah, United States

and more 34 locations

A Study To Evaluate D1 Receptor Occupancy (RO) Following Single Dose of PF-06412562 In Healthy Male Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: PF-06412562
Drug: 30 mg PF-06412562

First Posted Date: 2014-04-28

Last Posted Date: 2014-12-17

Lead Sponsor: Pfizer

Target Recruit Count: 5

Registration Number: NCT02124213

Locations: 🇸🇪
Karolinska Trial Alliance (KTA) M62, Huddinge, Stockholm, Sweden

A Study Of PF-06664178 In Patients With Advanced Solid Tumors

Phase 1

Terminated

Conditions: Neoplasms

Interventions: Drug: PF-06664178

First Posted Date: 2014-04-24

Last Posted Date: 2018-02-19

Lead Sponsor: Pfizer

Target Recruit Count: 31

Registration Number: NCT02122146

Locations: 🇺🇸
Swedish Medical Center, Seattle, Washington, United States
🇺🇸
USC/Norris Comprehensive Cancer Center / Investigational Drug Services, Los Angeles, California, United States
🇺🇸
USC/Norris Comprehensive Cancer Center, Los Angeles, California, United States

and more 7 locations

Prevenar (13v) Infant Drug Use Investigation

Completed

Conditions: Infants

Interventions: Drug: Prevenar (13v)

First Posted Date: 2014-04-21

Last Posted Date: 2017-06-19

Lead Sponsor: Pfizer

Target Recruit Count: 1087

Registration Number: NCT02119104

Safety and Efficacy of AN2728 Topical Ointment, 2% in Children, Adolescents, and Adults (Aged 2 Years and Older) With Atopic Dermatitis

Phase 3

Completed

Conditions: Dermatitis, Atopic

Interventions: Drug: AN2728 Topical Ointment, 2%
Drug: Matching vehicle control

First Posted Date: 2014-04-21

Last Posted Date: 2017-03-06

Lead Sponsor: Pfizer

Target Recruit Count: 764

Registration Number: NCT02118792

Locations: 🇺🇸
Anacor Investigational Site, Henrico, Virginia, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy